Agreed @pp. monthly cash burn of $1.2M per month is a bit high. Even if we remove the $12.4M write offs on the old excess inventories in China.However, Bub is a growth company and they need to spend for growth and to meet demands.Examples1. Increasing O2O stores in China from 138 to 300 to stock up bubs IFs.2. US demands accelerating, monthly sales scans of $1M plus.3. FDA approval process, lots of trials and people involved to satisfy FDA requirements. expected approval by Oct FY25.3. Bubs going into other countriesAs per above examples. Spending is justified if growth is strong and revenues keep on accelerating .IMHO.
(20min delay)